Education
About Us
Working with TipRanks
Follow Us
Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
RESEARCH TOOLSreports
3692 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$14.96 - HK$25.90
Previous CloseN/A
Volume4.63M
Average Volume (3M)11.35M
Market Cap
HK$140.67B
Enterprise ValueHK$77.81B
Total Cash (Recent Filing)¥22.43B
Total Debt (Recent Filing)¥4.30B
Price to Earnings (P/E)29.6
Beta0.86
Next Earnings
Aug 27, 2025EPS Estimate
0.36Next Dividend Ex-Date
Jul 03, 2025Dividend Yield1.45%
Share Statistics
EPS (TTM)0.80
Shares Outstanding5,935,650,000
10 Day Avg. Volume16,187,221
30 Day Avg. Volume11,349,183
Financial Highlights & Ratios
PEG Ratio0.94
Price to Book (P/B)N/A
Price to Sales (P/S)7.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.70Price Target Upside8.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Hansoh Pharmaceutical Group Company Limited News
PremiumCompany Announcements
Hansoh Pharmaceutical Declares Final Dividend for 2024
PremiumCompany Announcements
Hansoh Pharmaceutical Schedules Board Meeting for Year-End Results
PremiumCompany Announcements
Hansoh Pharmaceutical Receives Clinical Trial Approval for New Drug---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHansoh's FY24 performance was in line with expectations, reporting revenue of RMB12.26bn and attributable net income of RMB4.37bn.
Product Sales GrowthSales of innovative drugs, excluding collaboration revenue, saw strong growth of +28.2% YoY, totaling RMB7.9bn.
Strategic PartnershipsHansoh out-licensed oral GLP-1 drug to MSD, with an upfront payment of US$112mn and potential milestone payments up to US$1.9bn, plus future sales royalties.
Bears Say
Market CompetitionThe global development of oral GLP-1 drugs continues to attract significant attention for their ease of use and scalability in production.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.40%
Mutual Funds
― Other Institutional Investors
95.70% Public Companies and
Individual Investors
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$14.96 and its highest was HK$25.90 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$140.67B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Aug 27, 2025 which is in 142 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Mar 21, 2025. The company reported HK$0.299 earnings per share for the quarter, beating the consensus estimate of HK$0.246 by HK$0.053.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Annually dividend of HK$0.343 which represents an annual dividend yield of 1.45%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.36.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 5,935,650,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.299 in its last earnings report, beating expectations of HK$0.246. Following the earnings report the stock price went down -5.634%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
---
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$25.70 (8.44% Upside)
HK$25.70 (8.44% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
54.52%
12-Months-Change
Fundamentals
Return on Equity
16.09%
Trailing 12-Months
Asset Growth
-7.38%
Trailing 12-Months
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
---
3692 Stock 12 Month Forecast
Average Price Target
HK$25.70
▲(8.44% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Best Analysts Covering 3692
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+28.90%
reiterated a buy rating 5 months ago
Copying Rebecca Liang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.90% per trade.
---